John Levine - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock John Levine's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
John Levine
Verified
Contributor, CircleID
Trumansburg
Beats
music,
Content
By John Levine| Wiley Online Library Verified Conflicts of Interest Research support from Biogen, Incyte, and Mesoblast; royalties from a GVHD biomarker patent licensed to Viracor, and consulting fees from Bluebird Bio, Editas, Equillium, Inhibrx, Ironwood, Kamada, MaaT Pharma, Mesoblast, Sanofi, and X4 Pharmaceuticals. References 1, , , et al., “Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis,” New England Journal of Medicine 388, no. 25 (2023): 2338–2348.
Correction: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002 - Bone Marrow Transplantation
By Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Patrice Chevallier, Andrew Harris, Ernst Holler, David Beauvais, Richard T Maziarz, Johannes Schetelig, Margaret MacMillan, John Levine| Nature Verified Correction to: Bone Marrow Transplantation https://doi.org/10.1038/s41409-023-02110-4, published online 25 September 2023In this article the funding support is correct within the paper but during the submission process, it appears that the wrong grant number was selected. This paper is a BMT CTN protocol only, and is not CIBMTR related. As such only the BMT CTN Grant number (U24HL138660) should be selected. The original article has been corrected.
By John Levine| Wiley Online Library Verified Conflicts of Interest Research support from Biogen, Incyte, and Mesoblast; royalties from a GVHD biomarker patent licensed to Viracor, and consulting fees from Bluebird Bio, Editas, Equillium, Inhibrx, Ironwood, Kamada, MaaT Pharma, Mesoblast, Sanofi, and X4 Pharmaceuticals. References 1, , , et al., “Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis,” New England Journal of Medicine 388, no. 25 (2023): 2338–2348.
Company Info
CircleID
CircleID is a collaborative news and opinion website where professionals come to connect, inform and be informed about the latest developments that are shaping the Internet. Dedicated to all critical Internet issues: Technology, standards, security, policy, law, governance, commerce, and more.
Founded: 2002